Table 1 Demographic details and baseline characteristics of study participants
From: Systemic Immuno-metabolic alterations in chronic obstructive pulmonary disease (COPD)
|  | HNS (n = 16) | HS (n = 13) | TS-COPD (n = 14) | p-value |
|---|---|---|---|---|
Age (y) | 53.38 ± 10.43 | 60.15 ± 8.754 | 68.36 ± 8.924 | < 0.001 |
Gender (M/F) | 8 M/8F | 13 M/0F | 14 M/0F | N/A |
BMI | 24.31 ± 3.909 | 23.71 ± 2.814 | 19.75 ± 3.12 | < 0.01 |
Fasting BSL (mg/dL) | 88.63 ± 12.1 | 91.54 ± 16.22 | 95.31 ± 11.68 | NS |
Smoking history, Pack years (Ex:Current) | N/A | 32.69 ± 17.37 (2:11) | 39.45 ± 29.98 (6:8) | NS |
FEV1 (% Predicted) | 104.3 ± 10.57 | 97.72 ± 9.394 | 51.09 ± 26.24 | < 0.001 |
FVC (% Predicted) | 102.3 ± 13.3 | 95.08 ± 11.46 | 85.85 ± 20.78 | < 0.05 |
FVC/FEV1% | 102.5 ± 6.387 | 103.3 ± 4.426 | 58.12 ± 19.49 | < 0.001 |
COPD gold stage (I/II/III/IV) | N/A | N/A | 3/2/6/3 | N/A |
Monocytes (%) | 5.786 ± 0.699 | 7.5 ± 1.446 | 7.556 ± 1.667 | < 0.01 |
(/μL) | 435.9 ± 119 | 595.6 ± 148.9 | 619.4 ± 224 | < 0.05 |
Neutrophils (%) | 55.93 ± 12.39 | 53.58 ± 8.051 | 60.44 ± 6.966 | NS |
(/μL) | 4186 ± 1170 | 4390 ± 1431 | 5033 ± 1656 | NS |
Lymphocytes (%) | 34.43 ± 10.41 | 34.83 ± 7.158 | 29.11 ± 5.667 | NS |
(/μL) | 2612 ± 1124 | 2810 ± 792.1 | 2359 ± 705.4 | NS |
Eosinophils (%) | 3.857 ± 2.685 | 4.083 ± 3.37 | 2.889 ± 1.833 | NS |
(/μL) | 280.3 ± 194.4 | 345.8 ± 371.1 | 266.2 ± 260.8 | NS |